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Most direct-acting antivirals (DAAs) that are being developed as therapy against hepati-
tis C virus target the NS3/4A protease, the NS5A protein, and the NS5B polymerase.
The latter enzyme offers different target sites: the catalytic domain for nucleos(t)ide ana-
logues as well as a number of allosteric sites for nonnucleos(t)ide inhibitors. Two NS3/
4A protease inhibitors have been approved recently, and more than 40 new NS3/4A,
NS5A, or NS5B inhibitors are in development. These agents can achieve very high cure
rates when combined with pegylated interferon-a and ribavirin and show promising
clinical results when administered in all-oral combinations. In addition to the more
canonical drug targets, new alternative viral targets for small-molecule drug develop-
ment are emerging, such as p7 or NS4B and viral entry. Future research will need to
define well-tolerated and cost-effective DAA combinations that provide the highest rates
of viral eradication in all patients (including those with advanced liver disease), the
broadest spectrum of action on viral genotypes showing minimal or no clinical resist-
ance, and the shortest treatment duration. (HEPATOLOGY 2013;58:428-438)
F
or more than a decade, the standard treatment
of chronic hepatitis C virus (HCV) infection has
been based on the combination of pegylated
interferon-a (PEG-IFN) and ribavirin (RBV) adminis-
tered for 24 or 48 weeks. These regimens eradicate
infection in 40% to 50% of treated patients with ge-
notype 1 (HCV-1) infection and 80% of treated
patients with genotype 2 (HCV-2) and 3 (HCV-3)
infection. In addition, PEG-IFN/RBV regimens are
poorly tolerated and contraindicated in a high per-
centage of patients. In order to address the shortcom-
ings of PEG-IFN/RBV therapy, new direct-acting
antivirals (DAAs) are being developed that target spe-
cific HCV functions. The recent approval of the first
two NS3/4A oral protease inhibitors (PIs), boceprevir
(BOC) and telaprevir (TVR), for use in combination
with the PEG-IFN/RBV backbone has represented a
dramatic advance in the efficacy of pharmacotherapy
against chronic hepatitis C. With this new triple ther-
apy regimen, patient cure rates for chronic HCV-1
infection have increased to 70% to 80% while
significantly reducing treatment duration. However,
these recently approved DAA regimens are poorly tol-
erated, are associated with a high pill burden and an
inconvenient dosing frequency, and are not indicated
for genotypes other than HCV-1. Moreover, selection
of DAA-resistant viral variants occurs in patients who
respond poorly to the PEG-IFN/RBV component of
combination therapy. In light of these limitations,
newer DAAs are being developed to identify regimens
that are more convenient and efficacious, are better
tolerated, are pan-genotypic, and have a low propen-
sity to develop viral resistance. These are primarily
targeted at the NS3/4A protease, NS5A protein, or
NS5B RNA-dependent RNA polymerase. In addition,
other less-studied viral proteins (e.g., NS4B or p7) or
the virus entry steps have been recently demonstrated
to be druggable. The ultimate goal in HCV research
is to develop a broadly efficacious, IFN-free all-oral
therapy. Toward this aim, several clinical trials com-
bining only oral antivirals have begun to show very
promising results. In this review, we summarize the
Abbreviations: ASV, asunaprevir; BOC, boceprevir; DAA, direct-acting antiviral; DCV, daclatasvir; DNV, danoprevir; FQ, ferroquine; HCV, hepatitis C virus;
NI, nucleos(t)ide inhibitor; NNI, nonnucleos(t)ide inhibitor; PEG-IFN, pegylated interferon-a; PI, protease inhibitors; RBV, ribavirin; RdRp, RNA-dependent
RNA polymerase; SIL, silibinin; SOF, sofosbuvir; SVR, sustained viral response; TVR, telaprevir.
From the 1A.M. e A. Migliavacca Center for the Study of Liver Disease, 1st Division of Gastroenterology, Fondazione IRCCS Ca Granda Ospedale Maggiore
Policlinico, Milan, Italy; and 2Istituto Nazionale Genetica Molecolare, Milan, Italy.
Received January 24, 2013; accepted February 27, 2013.
428
progress in the development of DAA-based therapies,
with particular emphasis on those compound classes/
combinations that have shown the most encouraging
antiviral activity in the clinic.
Inhibitors of the NS3/4A Serine Protease
The HCV NS3/4A protease is a heterodimeric ser-
ine protease composed of the NS3 180 N-terminal
amino acids and a short central hydrophobic domain
of the NS4A protein, a protease coactivator1 (Fig. 1A).
The protease activity of the NS3/4A complex is re-
sponsible for the proteolytic maturation of a large por-
tion of the nonstructural region of the HCV
polyprotein, NS3 to NS5B. A number of peptidomi-
metic active site inhibitors have now been developed.
From a chemical point of view, these can be divided
into three main categories: (1) covalent linear PIs, (2)
noncovalent linear PIs, and (3) noncovalent macrocy-
clic PIs. Macrocyclic PIs can be further classified as P3-
P1 macrocycles or P4-P2 macrocycles (Fig. 1B).
In the scientific community, the terms “first-gener-
ation” and “second-generation” are used to define succes-
sive PI generations. First-generation NS3/4A PIs are
defined as agents that display potent activity on HCV-1
but oppose a low barrier to selection of resistant viral var-
iants and are not effective on all viral genotypes. First-
generation NS3/4A PIs are in turn distinct in “first-wave”
(i.e., BOC and TVR, both covalent linear inhibitors) and
“second wave” (noncovalent linear or macrocyclic inhibi-
tors). Conversely, second-generation NS3/4A PIs are
defined as agents that pose a high barrier to the develop-
ment of viral resistance, retain activity against the viral
variants that are resistant to first-generation compounds,
and are active across all HCV genotypes.
First-Generation NS3/4A HCV PIs. The currently
approved NS3/4A inhibitors, BOC2 and TVR,3 con-
tain a a-ketoamide warhead that forms a covalent re-
versible bond with the protease catalytic serine (Fig.
1B). Mutations associated with resistance to TVR or
BOC readily occur at several positions close to the
protease active site and are selected within a few days
of monotherapy (Fig. 1A). These mutations include
V36A/M/L, T54A/S, R155K/M/S/T, A156S (confer-
ring low- to medium-level resistance), and A156T/Y
(conferring high-level resistance).4
A number of second-wave, first-generation NS3/4A
PIs are in advanced clinical development. These
include the noncovalent linear PIs faldaprevir/BI
201335,5 asunaprevir/BMS-650032 (ASV),6 sovaprevir/
ACH-1625,7 and GS-94518; the noncovalent P3-P1
macrocyclic PIs simeprevir/TMC435,9 danoprevir/
RG7227/ITMN-191 (DNV),10 ABT-450,11 and GS-
925612; and the noncovalent P4-P2 macrocyclic PI vani-
previr/MK-700913 (Fig. 1B). These agents are character-
ized by potent activity on genotype 1 HCV replicons
(typically, low-nM EC50). This translates into clinical ef-
ficacy in HCV-1 patients similar to that of BOC or
TVR, leading to a decrease in circulating viral RNA of
3.5 to 4.5 log IU/mL when administered as monother-
apy for a few days. Unlike their first-wave counterpart,
second-wave PIs do not have the chemical reactivity
needed to covalenty attack their target, leading to gener-
ally better tolerability. In addition, these agents have
pharmacokinetic profiles compatible with once or once
daily dosing (low-dose ritonavir boosting is used with
DNV and ABT-450 in order to decrease dosing fre-
quency). Although some second-wave NS3/4A PIs have
a significantly broader spectrum of action on the differ-
ent HCV genotypes compared with their predecessors,
including activity on HCV-4, these agents are not pan-
genotypic, being invariably inactive on genotype 3.14
Along with the restricted genotype coverage, the
genetic barrier to resistance to first-generation NS3/4 PIs
is low, with extensive cross-resistance observed between
the different compound classes. In particular, mutations
of Arg155 have been shown to confer broad cross-resist-
ance to all first-generation inhibitors. Conversely, muta-
tions of Val36 or Thr54 have been observed exclusively
in association with covalent linear inhibitors (first- wave),
and mutations of Asp168 are specifically found to confer
mutation to noncovalent peptidomimetic inhibitors (sec-
ond-wave, either linear or macrocyclic).14
Second-Generation Active Site and Allosteric NS3/
4A PIs. MK-5172 (Fig. 2B) is a second-generation
NS3/4A PI with pan-genotype antiviral activity and
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improved resistance profile.15 Importantly, this agent
maintains antiviral activity against most mutations that
confer resistance to first-generation PIs, such as the
two multidrug-resistant variants R155K and D168A.
A recent crystallographic study analyzing the molecular
basis of drug resistance against NS3/4A PIs revealed
that TVR, DNV, and vaniprevir interact directly with
the residues that confer resistance upon mutation,
whereas MK-5172 interacts in a unique conformation
with the catalytic triad, avoiding direct contact with
R155 and D168.16 No viral breakthrough has been
observed in HCV-1 patients who received this drug
alone for 7 days,17 suggesting a higher barrier to resist-
ance compared with first-generation inhibitors. More-
over, HCV-3 patients responded with a robust decline
in viral RNA at the higher drug doses. ACH-2684,
a P3-P1 macrocyclic inhibitor, is another second-gener-
ation HCV PI currently being tested in a phase 1 clin-
ical trial. ACH-2684 has potent biochemical activity
against HCV genotypes 1-6 and against known resist-
ant variants.18 It is worth noting the recent discovery
of a new class of allosteric NS4/4A PIs that bind at
the interface between the NS3 protease and helicase
domains.19 These agents exhibit a unique and novel
resistance profile in vitro, implicating mutations of
amino acids located at the allosteric drug binding site
(M485 and V630). Comparable inhibition against ge-
notypes 1, 3a, 5, and 6 but loss of activity against ge-
notypes 2a and 4 were reported for these compounds.
NS5A Inhibitors
HCV NS5A is a multifunctional, dimeric protein
essential for HCV RNA replication and virion assem-
bly.1 The NS5A protein structure consists of three
Fig. 2. Structure of the NS5A protein and resistance to NS5A inhib-
itors. (A) Three-dimensional structure of NS5A protein domain I (Pro-
tein Data Bank entry: 1ZH1). The structural Zn11 ion is in gray. Amino
acids corresponding to main resistance mutations are evidenced and
numbered. Substitutions of Y93 represent primary mutations, whereas
mutations of position P58 act as a secondary mutation.23 Other posi-
tions that are mutated in NS5A-resistant HCV variants are not visible
in the domain I crystallographic structure. (B) Chemical structures of a
selected NS5A inhibitor.
Fig. 1. Structure of the NS3/4A protease and resistance to prote-
ase inhibitors. (A) Three-dimensional structure of an NS3/4A protease
domain–inhibitor complex (Protein Data Bank entry: 3M5L). NS3 is
depicted in green, NS4A in red. The structural Zn11 ion is in gray. The
amino acids corresponding to the main resistance mutations are num-
bered. (B) Chemical structures of selected protease inhibitors.
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domains: domain I (amino acids 1-213), domain II
(amino acids 250-342), and domain III (amino acids
356-447). The crystal structure of domain I has been
crystallized in a dimeric form containing a zinc-bind-
ing and an RNA-binding motif20 (Fig. 2A). NS5A
inhibitors, initially discovered by replicon screen-
ing,21,22 are believed to bind to domain I of NS5A
and result in the suppression of viral RNA synthesis.
Subsequent medicinal chemistry efforts led to the iden-
tification of extremely potent compounds characterized
by a peculiar dimer-like structure (Fig. 2B). The most
advanced of this “palindromic” NS5A inhibitor class is
daclatasvir /BMS-790052 (DCV),23 a compound with
picomolar activity against a broad range of HCV ge-
notypes. Clinically, single doses of DCV have been
associated with a sharp and long-lived reduction in vi-
remia.23 In spite of the potent antiviral activity, the
genetic barrier to resistance for DCV is low, especially
for genotype 1a. Thus, resistant variants emerge read-
ily, with the more relevant substitutions found at
NS5A residues 28, 30, 31, and 93 for genotype 1a
and residues 31 and 93 for genotype 1b.24 DCV is
currently being evaluated combination with PEG-IFN/
RBV as well as in IFN-free regimens, in combination
with sofosbuvir (polymerase nucleotide inhibitor), ASV
(PI), and/or BMS791325 (polymerase nonnucleoside
inhibitor).
Other NS5A inhibitors in clinical development
include GS-5885, ABT-267, PPI-461, ACH-3102, and
MK-8742. The latter two are early stage agents with a
higher barrier to resistance and which retain substantial
levels of potency against resistance mutations selected
by early NS5A inhibitors. These novel agents can thus
be viewed as second-generation NS5A inhibitors.25
NS5B Polymerase Inhibitors
The NS5B RNA-dependent RNA polymerase
(RdRp) is the enzyme directly responsible for the syn-
thesis of the HCV RNA genome.1 Similar to other
nuclei acid polymerases, NS5B has the typical right-
hand polymerase structure, consisting of a thumb do-
main and a fingers domain encircling the enzyme active
site located within the palm domain (Fig. 3A). Inhibi-
tors of the NS5B RdRp are classified into nucleos(t)ide
inhibitors (NIs) and nonnucleos(t)ide (NNI) inhibitors
(Fig. 3B).
Nucleos(t)ide Analogues. NIs target HCV RNA
synthesis at the catalytic site of the NS5B enzyme.
They are mimics of the natural polymerase substrates
and are incorporated by the polymerase in the nascent
RNA, leading to premature chain termination.
Nucleoside inhibitors need three phosphorylation steps
by cellular kinases to be converted to the active 50 tri-
phosphate form. Conversely, nucleotide polymerase
inhibitors are prodrugs of nucleoside 50 monophos-
phates, thus bypassing the rate-limiting step repre-
sented by the first phosphorylation step. Because of
the active site conservation, NIs have similar efficacy
across all HCV genotypes/isolates.26 For the same rea-
son, nucleos(t)ide inhibitors pose a high barrier to
Fig. 3. Structure of the NS5B RdRp and resistance to polymerase
inhibitors. (A) Structure of the HCV NS5B polymerase and binding
sites for nucleos(t)ide and NNIs. The palm, finger, and thumb domains
are colored green, red, and blue, respectively. Mn11 ions in the active
site in gray. The amino acids corresponding to the main resistance
mutations for different inhibitor classes are numbered. (B) Chemical
structures of selected NS5B polymerase inhibitors.
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development of drug resistance.27 Virtually all NIs in
development contain 20-C-methyl and 20-fluoro groups
at the sugar 20 position. The primary mutation associ-
ated with decreased susceptibility to these drugs is
NS5B S282T28 (Fig. 3A). The S282T mutation
severely reduces HCV replication capacity, explaining
the high barrier to resistance posed by 20 modified
NIs.27 Sofosbuvir/GS-7977 (SOF) (Fig. 3B) is cur-
rently the most advanced NI NS5B polymerase inhibi-
tor in clinical development (phase 3). SOF is a uridine
nucleotide monophosphate analogue (beta-D220-
deoxy-20-fluoro-20-C-methyluridine monophosphate).
The S282T mutation is the most common SOF resist-
ance mutation to emerge during resistance selection in
vitro.29 Whereas this mutation conferred resistance to
SOF in genotype 1 replicons, it only caused a very
minor shift in potency in genotype 2a, thus suggesting
that additional mutations in genotype 2a NS5B are
required for the resistant phenotype.29 Most impor-
tantly, to date, viral resistance has been observed rarely
in any SOF-based clinical study, regardless of the viral
genotype.30 SOF is currently studied in IFN-free com-
binations with a number of other DAAs, including
NS3/4A protease inhibitors (GS-938, simeprevir) and
NS5A inhibitor (DCV or GS-5885). Other nucleos(-
t)ide polymerase inhibitors in active clinical develop-
ment include mericitabine/RG7128 (prodrug of 20-
deoxy-20-fluoro-20-C-methylcytidine; phase 2), and
ALS-2200/VX-135 (structure undisclosed, phase 1).
NNIs. Unlike NIs, NNIs bind to less conserved al-
losteric sites found on the enzyme surface (Fig. 3A). In
contrast to NIs, these molecules have shown a re-
stricted spectrum of activity against the various HCV
genotypes26 and present a very low barrier to emer-
gence of resistance.27 The hallmark of all allosteric
HCV NNIs described so far is that, in contrast to
active site NIs, they are noncompetitive with nucleo-
tide triphosphate substrates and inhibit the polymerase
at a stage preceding the elongation reaction.1 Different
NNI binding sites are illustrated in Fig. 3B. These
include thumb site I (benzimidazole-binding site),
thumb site II (thiophene-binding site), palm site I
(benzothiadiazine-binding site), and palm site II (ben-
zofuran-binding site). Significant variability in the
amino acid sequence is observed at these sites, making
it difficult to achieve antiviral efficacy against different
genotypes or even HCV isolates within the same geno-
type. As a result, most reported NNIs are rather spe-
cific for genotype 1 or 1b.14
Several structurally related NNIs have been shown
to bind to the thumb site I.31 This class of inhibitors
interrupts the intramolecular contacts between the
thumb and the finger loop, thereby preventing the for-
mation of a productive enzyme/RNA complex.32
These agents are also known as finger loop inhibitors
and are characterized by having a common benzimida-
zole or indole chemical core (Fig. 3B). HCV variants
resistant to these agents carry mutations at positions
P495, P496, and T38933,34 (Fig. 3A). Clinically,
agents belonging to this class of NNIs display reduced
activity against genotype 1a compared with genotype
1b.35 Several thumb I NNIs are currently being inves-
tigated in phase 2 clinical trials, including BI 207127,
TMC647055, and BMS791325.
Thumb II NNIs bind to a cavity located at the base
of the thumb domain of NS5B (Fig. 3A). Mutations
at positions L419, M423, and I482 in the viral poly-
merase have been shown to confer resistance to this
class of compounds.36 Lomibuvir/VX-222 (Fig. 3B), a
tiophene carboxylic acid, and filibuvir/PF-868554, a
dihydropyranone derivative, are currently in phase 2
clinical trials.
The palm I NNI-binding site is located at the junc-
tion of the palm and the thumb domain of NS5B, in
proximity to the catalytic site. Benzothiadiazine com-
pounds such as setrobuvir/RG7790 (formerly
ANA598; Fig. 3B), ABT-333, and ABT-072 bind to
this NNI site. The most frequently resistant mutations
selected by these agents are C316Y, M414T, Y448H/
C, and S556G (Fig. 3A).37 These compounds are cur-
rently in phase 2 clinical trials. Acylpyrrolidines are yet
another class of palm I-binding compounds.38 In this
class, GSK625433 was advanced into phase 1 clinical
trials, but this study was halted because of adverse
effects noted in preclinical carcinogenicity studies.39
The palm II NNI-binding site partially overlaps
with the palm I site and is located proximal to the
junction between the palm and thumb domain. A class
of benzofurans was originally identified as an NNI
class binding to this site. These molecules select for re-
sistant mutants at residues L314, C316, I363, S365,
and M41440 (Fig. 3A). HCV-796 showed significant
activity in early stage clinical trials41 but was discontin-
ued because of adverse side effects. HCV variants re-
sistant to imidazopyridines, another HCV NNI
chemotype, carry mutations in the same site (C316Y)
as well as mutations in a b-hairpin loop (C445F,
Y448H, Y452H) located in close proximity to the cat-
alytic active site (Fig. 3A). In contrast to other NNIs,
imidazopyridines do not inhibit the enzymatic activity
of the purified RdRp, suggesting that these molecules
target the enzyme via a unique mechanism. Recent
data have revealed that imidazopyridine NNIs require
metabolic activation by CYP1A for its activity. The
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resulting metabolite, after forming a conjugate with
glutathione, directly and specifically interacts with
NS5B.42 Within this class of imidazopyridine NNIs,
tegobuvir/GS-9190 (Fig. 3B) is undergoing phase 2
clinical trials.
Presumably due to their barrier to resistance and re-
stricted genotype/subtype coverage, HCV polymerase
NNIs such as tegobuvir or filibuvir have provided dis-
appointing clinical results when combined with PEG/
RBV. Several NNIs, including setrobuvir, lomibuvir,
BI207127, BMS791325, ABT-333, and ABT-072 are
now being tested with more promising results in all-
oral, IFN-free combination regimens.
Emerging Targets for DAA Development
While many inhibitors of HCV protease, polymer-
ase, or NS5A are at an advanced development stage,
new classes of direct-acting antivirals targeting less
explored viral functions have begun to appear on the
horizon.
NS4B is an RNA-binding integral membrane pro-
tein required for the biogenesis of the membranous
web required for the formation of HCV RNA replica-
tion complex.1 Several classes of NS4B inhibitors have
been identified recently.43 Clemizole, a first-generation
antihistamine, inhibits NS4B RNA-binding, thereby
preventing HCV RNA replication.44 Clemizole-resist-
ant variants carry mutations at position W55 and
R214 in the NS4B protein. An ongoing proof-of-con-
cept study is evaluating the safety and efficacy of clem-
izole monotherapy in treatment-na€ıve HCV-infected
patients. Preliminary data reveal that clemizole, while
inactive as a single agent, when combined with PEG-
IFN and RBV may result in a more efficacious reduc-
tion in viral load than PEG-IFN/RBV alone.45
Unexpectedly, very recent data point to NS4B as a
candidate target for the anti-HCV action of silibinin
(SIL).46 SIL is an intravenous drug that has recently
been administered to HCV-positive liver transplant
recipients, leading in some instances to eradication of
the infection. In cell culture, SIL potently inhibits
HCV RNA replication for genotype 1a and genotype
1b, but not for genotype 2a. Mutations in NS4B,
obtained either by selection in cell culture (Q203R) or
observed in a liver transplant recipient experiencing
viral breakthrough under SIL monotherapy (F98L1
D228N), were found to confer in vitro resistance to
SIL. These new exciting data point to the possibility
that an already approved agent may be added to the
growing armamentarium of HCV DAAs. Unfortu-
nately, the intravenous mode of administration will
ultimately limit the use of SIL in all-oral DAA
combinations.
The HCV p7 protein is a viroporin1 critical for the
release of infectious virions. When its cation channel
activity is pharmacologically blocked, virus production
is significantly reduced.47 A number of HCV p7
inhibitors have been identified, such as amantadine,
rimantadine, long-alkylated iminosugar, and amiloride
derivatives. The in vitro sensitivity to HCV to these
drugs is highly genotype-dependent, presumably
because of the high sequence variability associated with
the p7 genetic region. To date, none of these p7-
directed agents has demonstrated any significant clini-
cal activity.
Another way to potentially limit acute as well as
chronic HCV infection would be to prevent virus
entry into the noninfected cells. Ferroquine (FQ), a
novel antimalarial currently undergoing clinical evalua-
tion, has been reported recently to inhibit HCV entry
in cell culture at the membrane fusion step.48 FQ-re-
sistant HCV was selected with a single resistance-con-
ferring mutation in the E1 envelope protein (S327A).
FQ may therefore represent a novel direct antiviral
agent ready to be combined with other DAAs for all-
oral therapy.
Future Treatment Strategies
Although there are still some concerns regarding
how many of the anti-HCV drugs currently in devel-
opment will actually hit the market, it is clear we are
on the verge of a revolution in the treatment of
chronic hepatitis C. This revolution, at least for the
hard-to-cure HCV genotypes 1 and 4, is likely going
to consist of a two- to three-step process that will ulti-
mately lead us to the holy grail of an all-oral, pan-gen-
otypic, IFN-free therapy. The first step forward in
anti-HCV therapy will be the introduction of a sec-
ond-wave PI to be used in combination with PEG-
IFN/RBV. This will be followed by NS5A and NS5B
inhibitors to be used with PEG-IFN/RBV in triple
therapy regimens or in quadruple therapy regimens in
combination with a second-wave PI. Finally, several
all-oral combinations will enter the market, likely
becoming the standard of care first therapeutic option
for all HCV genotypes.
PIs in Combination With PEG-IFN/RBV. One
of the main limitations of the first-wave PIs BOC and
TVR is tolerability when they are used with PEG-
IFN/RBV. This stems both from the induction of spe-
cific side effects as well as from the rather impractical
assumption mode that both compounds require.49
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These first-generation, first-wave PIs need to be taken
every 7 to 9 hours with food, causing a significant pill
burden that may lead to suboptimal adherence and
suboptimal efficacy. First-generation, second-wave PIs
such as simeprevir, faldaprevir, and ritonavir-boosted
DNV will be able to bypass this issue, as they are
being studied in phase 3 trials with once-daily dos-
ing.50 For HCV-1 patients, dosing convenience is
likely to be one of the main advantages of these PIs, as
phase 2b sustained viral response (SVR) rates of sec-
ond-wave PIs in combination with PEG-IFN/RBV do
not exceed those seen with first-wave PIs. Second-wave
PI triple therapies, in fact, achieve suboptimal response
rates in poor responders to PEG-IFN/RBV, patients
with cirrhosis, or HCV-1a patients.51,52 Moreover,
their resistance profile is largely similar to that of
BOC or TVR, meaning that second-wave PIs cannot
be considered as a rescue therapy. These drugs, how-
ever, can be a clinical breakthrough for patients with
non–genotype 1 infection, as they are active against ge-
notypes 2, 4, 5, and 6.53 This is especially significant
for HCV-4 patients that not only are on the rise in
many countries due to immigration from endemic
areas but also currently represent a large unsatisfied
medical need, given that TVR and BOC show little ef-
ficacy and are not reimbursed in this patient popula-
tion. Importantly, in a phase 2b study of HCV-4
patients receiving PEG-IFN/RBV and ritonavir-
boosted DNV, 100% achieved an SVR following a
course of 24 weeks of triple therapy.54
NS5A or NS5B Inhibitors in Combination With
PEG-IFN/RBV. NS5A inhibitors and NS5B poly-
merase inhibitors will enter the HCV market in a sec-
ond phase and will probably be, at least for a short
time, associated with PEG-IFN/RBV therapy in substi-
tution of first-wave PIs and in competition with sec-
ond-wave PIs. Whether they will provide a true
innovation in terms of viral cure rates, safety profile,
or patient tolerability is still to be demonstrated. A 24-
week treatment of PEG-IFN/RBV plus DCV in
HCV-1–na€ıve patients has been shown to attain SVR
rates that range from 87% for HCV-1b patients to
58% for HCV-1a. These rates are similar to TVR or
BOC triple-combination regimens, and also confirm
the low barrier to resistance of first-generation NS5A
inhibitors in the 1a subtype.14,55 NS5A inhibitors
seem better fit as partners of other DAAs56 as shown
by the very promising data obtained by a 24-week
quadruple regimen of PEG-IFN/RBV plus DCV and
ASV (PI) in HCV-1 patients with a previous null
response to PEG-IFN/RBV. This regimen was associ-
ated with a 100% SVR rate in a small pilot study and
is now being explored in phase 3 studies.57 Although
this is an impressive performance gain compared with
TVR/BOC, which reach subpar SVR rates (30%-35%)
in this population, this quadruple regimen is still rela-
tively complex for patients, has a largely unknown
safety profile, and still needs to be explored in patients
with cirrhosis.
Equally impressive SVR rates have been seen with a
12-week regimen of PEG-IFN/RBV plus the NS5B
nucleotide inhibitor SOF, as 90% of 51 HCV-1–na€ıve
patients (and 77% of HCV-1a–na€ıve patients)
achieved SVR12 in the phase 2 ATOMIC study.58
This regimen will improve SVR rates in HCV-1a
patients, as NS5B NI activity is not influenced by
HCV-1 subtype, but is unlikely to revolutionize the
field in HCV-1b patients. In fact, when comparing the
SVR rates of the ATOMIC study to phase 3 trials of
BOC/TVR in HCV-1b patients with similar viral and
disease characteristics, the actual SVR gain quantifiable
in the 10% to 15% range. Importantly, equally high
SVR rates have been achieved by the PEG-IFN/RBV
plus SOF combination in HCV-4 patients (82%).
All-Oral IFN-Free Regimens. The first all-oral
anti-HCV regimen will be likely available in 2014 for
HCV-2 and HCV-3 patients. Phase 3 studies investi-
gating a 12-week course of the NS5B inhibitor SOF
in combination with RBV are already fully enrolled
and completed, and final results are expected for the
second semester of 2013. This regimen has proven to
be particularly effective in the phase II ELECTRON
study, where 100% rates were obtained by this combi-
nation in HCV-2 and HCV-3 patients.59 For HCV-1
patients in the ELECTRON study, this regimen
turned out to be less effective, as SVR rates ranged
from 84% (na€ıve patients) to a disappointing 10% in
the treatment-experienced patients.59 In the National
Institutes of Health–sponsored SPARE study, 25
HCV-1–na€ıve patients were treated with SOF and
RBV for 24 weeks. The SVR12 rate was 72%,60 not
dissimilar from the current TVR/BOC-based standard
of care. This study should not be overlooked, as it was
obtained in a cohort of patients enriched in known
predictors of treatment failure such as advanced fibro-
sis (24% of patients), African American ethnicity
(72%), and interleukin-28B CT/TT (84%). Taken to-
gether, these data indicate that this regimen might be
an effective treatment option only for easier-to-cure
patients, including those infected with HCV-1b and
interleukin-28B CC and patients with mild disease,
while probably being suboptimal in patients with
harder-to-cure HCV disease, especially those who have
failed previous PEG/IFN therapy.
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The combination of two or more DAAs is funda-
mental to achieve more potent and broad HCV RNA
suppression and avoid IFN in HCV-1 patients. Several
regimens meeting these requirements are in advanced
phase of development.61 The optimal regimen should
combine a drug with potent antiviral activity (PI or
NS5A inhibitor) with a drug with a high genetic bar-
rier to resistance (NS5B NI); however, high SVR rates
have been achieved by regimens that are driven more
by the drug portfolio of the various pharmaceutical
companies than by rational mixing and matching of
DAAs. A quadruple therapy regimen consisting of 12
weeks of a ritonavir-boosted PI (ABT-450/r) plus an
NS5B NNI (ABT-333) and an NS5A inhibitor (ABT-
267) obtained SVR rates of 97.5% in 79 HCV-1–n€aive
patients and 93.3% in 45 previous null-responders to
PEG-IFN/RBV, with no significant differences in
HCV-1a or HCV-1b patients.62 A similar 12-week regi-
men of ASV (PI) plus DCV (NS5A inhibitor) plus
BMS791325 (NS5B NNI) reached 94% SVR in 16
HCV-1–na€ıve patients.63 These impressive numbers
compare well with what today could be considered the
optimal IFN-free regimen (i.e., the combination of the
NS5A inhibitor DCV and the NI NS5B inhibitor
SOF). This regimen, when given for 12 weeks, achieved
an SVR4 of 98% in 41 HCV-1–na€ıve patients.64
Remaining Issues
Although treatment of chronic HCV infection is
advancing at such a fast pace that keeping a strong
grip on drug development can be problematic at times
even for experts, some common themes surface from
most if not all ongoing studies (Table 1). First, there is
a widespread perception that most investigational
agents for the treatment of chronic hepatitis C are
being explored in easy-to-cure populations, at least
partially devoid of negative prognostic factors.65 The
lack of consistent safety and efficacy data in patients
with advanced fibrosis/cirrhosis represents a major
drawback in most, if not all, regimens. Although cir-
rhosis is likely going to lose its negative predictive
power as a response moderator once potent anti-HCV
regimens are available, it might nonetheless remain a
Table 1. Developing HCV Treatment Regimens
Therapeutic Regimen Advantages Over SOC 2013 Open Issues
IFN-containing regimens
PEG-IFN 1 RBV 1 second-wave PI Improved tolerability Cost-effectiveness
Reduced pill burden Specific side effects
Effective in non–HCV-1 patients Limited efficacy in HCV-1a
Drug-drug interactions
PEG-IFN 1 RBV 1 NS5A inhibitor Improved tolerability Cost-effectiveness
Reduced pill burden No data in patients with cirrhosis
Limited efficacy in HCV-1a
Drug-drug interactions
PEG-IFN 1 RBV 1 NS5B NI Improved tolerability Cost-effectiveness
Reduced pill burden No data in patients with cirrhosis
Effective in HCV-1a patients
Effective in non HCV-1 patients
PEG-IFN 1 RBV 1 second-wave
PI 1 NS5A inhibitor
Effective in HCV-1a patients Tolerability
Effective in non HCV-1 patients Pill burden
No data in patients with cirrhosis
Drug-drug interactions
IFN-free regimens
NS5B NI 1 RBV Improved tolerability Cost-effectiveness HCV-2/3
Effective in HCV-2 and HCV-3 patients Pill burden (RBV component)
Effective in HCV-1a patients Limited efficacy in difficult-to-cure patients
Second-wave PI 1 NS5A inhibitor Reduced pill burden Drug-drug interactions
Improved tolerability Limited efficacy in HCV-1a
Second-wave PI 1 NS5A inhibitor 1
NS5B NNI6RBV
Improved tolerability Pill burden
Effective in HCV-1a patients Drug-drug interactions
Limited data in patients with cirrhosis
NS5B NI 1 NS5A inhibitor Improved tolerability Limited data in patients with cirrhosis
Reduced pill burden
Fixed-dose combination
Effective in HCV-1a and in non HCV-1 patients
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key determinant of reduced safety with some regimens.
Indeed, some drugs have side effects that might be
worrisome in patients with cirrhosis, such as increased
bilirubin with simeprevir,66 while others (such as ASV)
show significant pharmacokinetic modifications in
patients with impaired liver function,67 and thus need
to be managed with caution in this group of patients.
The same safety questions need to be ascertained in
post–liver transplantation patients as well as those on
the transplant waiting list. To date, we only have two
very preliminary case reports of posttransplant fibros-
ing cholestatic hepatitis C patients who reached an
SVR with either a triple therapy regimen of PEG-
IFN/RBV and DCV68 or an IFN-free regimen of
DCV plus SOF,69 in each case without any significant
safety issue and without any clinically relevant drug-
drug interaction with the ongoing immunosuppressive
regimen. Real-life studies of IFN-free regimens have
shown surprisingly low rates of adherence to the cor-
rect treatment schedule and lower SVR rates compared
with sponsored studies, meaning that once we move
drugs into more difficult-to-cure patients, we might
not completely replicate the data obtained by phase II
trials.60,70
Affordability of some of these innovative regimens
will also be an issue. Whether anti-HCV regimens that
provide small benefits in terms of SVR but radically
improve patient tolerability will be deemed cost-effec-
tive by national health systems and hence be reim-
bursed universally is unclear. Given that cost-effective
drugs such as TVR/BOC71,72 are still not reimbursable
in many countries, it is possible that these innovative
regimens will be confined to groups of patients in
whom TVR/BOC or PEG-IFN/RBV are either ineffec-
tive or unsafe. This might create a paradox where
pharmaceutical innovation might not translate into
clinical innovation, with some patients receiving mar-
ginally less effective and less tolerable drugs for cost-
containing issues.73 This might reduce the penetration
of treatment into key cohorts of infected patients, pre-
venting anti-HCV therapy from playing a major role
in containing the spread of the disease and in reducing
the rate of progression to cirrhosis in resource-con-
strained countries.
The last open issue that often goes unnoticed when
discussing future anti-HCV drugs is whether drug re-
sistance will emerge as a clinical problem with all oral
IFN-free regimens.4 Resistance to TVR/BOC has lim-
ited clinical significance as HCV quasispecies reverts to
wild-type virus in a relatively short period.74 This is
explained by the lack of a stable genetic reservoir for
HCV and by the replication unfitness of most resistant
variants to TVR/BOC. Whether this last point holds
true for other classes of DAA needs to be discussed.
NS5B NIs are characterized by a high barrier to resist-
ance, as the S282T mutation associated with decreased
susceptibility to this class of compounds dramatically
reduces HCV replication capacity. This means that this
mutation is very rarely found as a pretreatment natu-
rally occurring variant and is also seldom found at the
time of relapse.30 However, NS5B NIs require com-
pounds from other classes to achieve maximal SVR
rates. Resistance to first-generation NS5A inhibitors,
ideal partners for an NS5B NIs, have been shown to
occur naturally and in some cases to persist as the dom-
inant viral strain for at least 48 weeks following treat-
ment failure.75,76 In a Japanese study of HCV-1
patients treated with 24 weeks of ASV and DCV,
DCV-resistant variants were found in 20% of patients
at baseline. In virological failures, when NS3 and NS5A
resistance-associated variants were detected together
(NS3: D168A/V; NS5A: L31M/V-Y93H), DCV-resist-
ant substitutions persisted through 48 weeks, whereas
ASV-resistant substitutions were no longer detectable.77
It is too early to tell if this finding should alarm us,
since the ASV-DCV combination is considered subopti-
mal in terms of genetic barrier to resistance, but it
shows that not all we have learned from TVR/BOC
can be safely translated to future anti-HCV drugs.
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